Anzeige
Mehr »
Sonntag, 25.01.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q8LD | ISIN: BMG210A71016 | Ticker-Symbol: MX6A
Frankfurt
23.01.26 | 15:25
0,825 Euro
-0,60 % -0,005
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
GRAND PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
GRAND PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8100,87024.01.
0,8100,87023.01.

Aktuelle News zur GRAND PHARMACEUTICAL GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoGRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE NDA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX IS ACCEPTED BY THE NMPA1
31.12.25GRAND PHARMA (00512): CONNECTED TRANSACTION: ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA JIUFU BIOTECHNOLOGY CO., LTD. AND BAODING JIAHE ...1
29.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST ADRENALINE NASAL SPRAY INTRODUCED BY THE GROUP FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS ...1
23.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES THE WORLD'S FIRST ADRENALINE NASAL SPRAY FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS2
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln
17.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530, ...-
08.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 ...1
04.12.25GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS1
10.11.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: GLOBAL INNOVATIVE COMBINATION PRODUCT RYALTRIS NASAL SPRAY IS APPROVED TO BE COMMERCIALIZED IN CHINA1
09.10.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC ...-
24.09.25GRAND PHARMA (00512): INTERIM REPORT 2025-
24.09.25GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
24.09.25GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
23.09.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE3
08.09.25Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres352Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading...
► Artikel lesen
08.09.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ...2
27.08.25GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTION-
19.08.25GRAND PHARMA (00512): 2025 INTERIM RESULTS ANNOUNCEMENT1
05.08.25GRAND PHARMA (00512): DATE OF BOARD MEETING1
07.07.25SIR-Spheres Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms476Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms...
► Artikel lesen
07.07.25Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma325Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1